Logo

Podcasts

Tooltip

Tooltip

IMBRUVICA® is a preferred treatment for 1L patients with CLL and uIGHV[^13][^14]

IMBRUVICA® is a preferred treatment for 1L patients with CLL and uIGHV[^13][^14]

IMBRUVICA® is a preferred treatment for 1L patients with CLL and uIGHV[^13][^14]

Video test

References

[1]
García-Marco JA, Delgado J, Hernández --Rivas JA, et al. Update of the Grupo Español de Leucemia Linfocíta Crónica clinical guidelines of the management of chronic lymphocytic leukemia. Med Clin (Barc) 2017;148(8):381.e1-381.e8.
[2]
Wendtner C-M, Dreger P, Eichhorst B, et al. Onkopedia leitlinien. Chronische Lymphatische Leukämie (CLL, Onkopedia guidelines, chronic lymphocytic leukaemia). April 2019.
© Janssen Pharmaceutica (Pty)Ltd 2021. This site is published by Janssen Pharmaceutica (Pty)Ltd which is solely responsible for its content. It is intended for South African Healthcare professionals.
Cookie Settings
Logo